Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Symphony GenIsis

M&A STATUS
M&A LATEST DEAL TYPE
2 FINANCING ROUNDS
Description

Developer of cholesterol-lowering and diabetic drugs. The company's clinical programs include ISIS 301012, an antisense drug, which inhibits a protein for the synthesis and transport of the bad cholesterol involved in heart disease; Glucagon receptor, a cellular receptor for glucagon, one of the counter-regulatory hormones that oppose the action of insulin and helps maintain normal blood glucose levels; and The glucocorticoid receptor, which is an intracellular protein that serves as the receptor for the steroid hormones of the glucocorticoid family. The company operates as a subsidiary of ISIS Pharmaceuticals.

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Food Products
Primary Office
  • 7361 Calhoun Place
  • Suite 325
  • Rockville, MD 20855
  • United States

Symphony GenIsis Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Symphony GenIsis‘s full profile, request access.

Request full access to PitchBook

Symphony GenIsis Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Symphony GenIsis‘s full profile, request access.

Request full access to PitchBook

Symphony GenIsis Executive Team (1)

Name Title Board
Seat
Contact
Info
Neil Sandler Founding Partner